Polycystic Ovarian Syndrome. Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: Patients will be divided into four study groups (recipients of turmeric supplement capsules, cinnamon supplement, turmeric and cinnamon supplement, and control). A total of 160 samples
Sponsors
Tarbiat Modares University
Eligibility
Sex/Gender
Female
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Age 18 to 45 years Diagnosis of PCOS by a gynecologist (according to clinical, laboratory, and imaging symptoms) Not pregnant now Failure to receive infertility treatment Do not take hormonal drugs or any medication for at least the last 3 months Do not take any medication or nutritional supplements More than 4 years after the onset of menarche Absence of severe underlying disease
Exclusion criteria
Exclusion criteria: Do not take the desired drugs for at least 7 days a month The unwillingness of the participant to continue the participation for any reason Occurrence of any adverse or intolerable complications during the study due to the patient's complaint, or physician's diagnosis Occurrence of pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Irregular menstrual frequency. Timepoint: At the beginning of the study and after 12 weeks. Method of measurement: History, clinical and paraclinical examinations.;Hirsutism. Timepoint: At the beginning of the study and after 12 weeks. Method of measurement: History, clinical and paraclinical examinations.;Serum testosterone levels. Timepoint: At the beginning of the study and after 12 weeks. Method of measurement: History, clinical and paraclinical examinations.;Serum FAI (Free Androgen Index). Timepoint: At the beginning of the study and after 12 weeks. Method of measurement: History, clinical and paraclinical examinations.;Polycystic ovary. Timepoint: At the beginning of the study and after 12 weeks. Method of measurement: History, clinical and paraclinical examinations. | — |
Secondary
| Measure | Time frame |
|---|---|
| HOMA-IR (Homeostasis Model Assessment - Insulin resistance ). Timepoint: At the beginning of the study and after 12 weeks. Method of measurement: Paraclinical examinations.;FBS (Fasting blood sugar). Timepoint: At the beginning of the study and after 12 weeks. Method of measurement: Paraclinical examinations.;(MDA) Malone di aldehyde. Timepoint: At the beginning of the study and after 12 weeks. Method of measurement: Paraclinical examinations.;FSH ( Follicle-stimulating Hormone). Timepoint: At the beginning of the study and after 12 weeks. Method of measurement: Paraclinical examinations.;LH ( luteinizing hormone ). Timepoint: At the beginning of the study and after 12 weeks. Method of measurement: Paraclinical examinations. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactLeili Rahmatnezhad
The University of Tarbiat Modares
Outcome results
None listed